American Liver Foundation Celebrates AHRQ's Groundbreaking Report on NAFLD Prevalence and Impact

AHRQ's Landmark Report on Nonalcoholic Fatty Liver Disease

The American Liver Foundation (ALF) recently expressed its strong support for the Agency for Healthcare Research and Quality (AHRQ) following the release of a significant report regarding Nonalcoholic Fatty Liver Disease (NAFLD), a condition now referred to as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The report, titled "Inpatient Stays Related to Nonalcoholic Fatty Liver Disease, 2016-2022", delivers critical insights into the rising prevalence of this condition across the United States.

Findings of the Report

The AHRQ report reveals that NAFLD-related hospitalizations have surged by a staggering 88.1% from 2016 through 2022. Yet, this increase still accounts for only a small percentage—ranging between 1% and 2%—of all inpatient stays during the reviewed period. What stands out is that a substantial number of these admissions were categorized as secondary diagnoses. In most cases, NAFLD was identified in patients who were hospitalized primarily for unrelated medical issues, such as septicemia, obesity, pancreatic disorders, and alcohol-related ailments.

This troubling trend highlights not just the increasing rates of NAFLD but underscores the importance of better diagnosis and management in clinical settings. While it is estimated that one in four Americans are living with MASLD, the severe form of the disease, now termed Metabolic Dysfunction-Associated Steatohepatitis (MASH), affects between 1.5% to 6.5% of U.S. adults.

Advocacy and Future Directions

Lorraine Stiehl, the Chief Executive Officer of ALF, expressed her appreciation for AHRQ's initiative, stating, "On behalf of all Americans affected by liver disease, we sincerely thank AHRQ for conducting the first-ever NAFLD report, an important step in advancing understanding of the disease's prevalence and its impact on nearly 100 million people nationwide." The dedication shown by Senator Bill Cassidy in advocating for the report's release was also acknowledged, with hopes that it will pave the way for a more extensive study later this year.

The Economic Impact

The report takes a detailed look at the financial implications for individuals diagnosed with NAFLD, including costs incurred by patients and families, and government expenditures related to the condition. It raises awareness regarding the importance of addressing NAFLD before it escalates into severe liver conditions like MASH. Further discussion on the economic consequences of not treating NAFLD emphasizes the urgency for a proactive approach to liver health.

Conclusion

The American Liver Foundation urges continuous support for NAFLD awareness and research. Stiehl remarked, "This is a win for the liver community!" Encouraging further legislative and community advocacy is essential for obtaining the resources and support that Americans living with NAFLD require. For those interested in learning about their own risk for NAFLD, ALF offers a liver health quiz available in both English and Spanish.

To stay informed about NAFLD and liver health initiatives, and to access various resources related to liver wellness, please visit the American Liver Foundation at www.liverfoundation.org. Inquiries can also be made through their free helpline at 1-800-GO-LIVER (800-465-4837).